文献速递慢性肾脏病血液净化与透析

SGLT2抑制剂在不同心血管-肾脏-代谢基础疾病患者中的肾脏结局:系统综述与荟萃分析

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions: A Systematic Review and Meta-Analyses.
PubMed 文献 · J Am Soc Nephrol · 2024-09-04

结果显示SGLT2抑制剂可降低复合肾脏终点风险、减缓eGFR下降速率并降低血清肌酐持续倍增风险,且在多数亚组中效果一致。

要点

  • SGLT2抑制剂在合并心衰、CKD或2型糖尿病及其组合的患者中均减缓eGFR下降速率。
  • SGLT2抑制剂降低复合肾脏终点风险,但射血分数保留的心衰不伴2型糖尿病者除外。
  • SGLT2抑制剂降低2型糖尿病和CKD患者的肾衰竭风险。

核心结论

  • SGLT2抑制剂改善心衰、CKD和2型糖尿病队列的肾脏结局,且在不同共病组合患者中效果一致。

主要发现

  • 与安慰剂相比,SGLT2抑制剂在射血分数降低的心衰中降低复合肾脏终点风险41%(HR 0.59;95%CI 0.42-0.83)。
  • 在CKD中降低复合肾脏终点风险36%(HR 0.64;95%CI 0.55-0.73),在2型糖尿病中降低38%(HR 0.62;95%CI 0.56-0.69)。
  • 在总体人群中,SGLT2抑制剂降低血清肌酐持续倍增风险36%(HR 0.64;95%CI 0.56-0.72)。
  • SGLT2抑制剂减缓eGFR下降速率,且在多数有数据的亚组中肾脏结局效果一致。

临床怎么用

  • 对于合并心衰、CKD或2型糖尿病的患者,可考虑使用SGLT2抑制剂以改善肾脏结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Sodium-glucose cotransporter-2 (SGLT2) inhibitors slowed the rate of eGFR slope decline in patients with heart failure, CKD, and type 2 diabetes mellitus and in all combinations of multimorbid conditions among these diseases. SGLT2 inhibitors decreased kidney composite outcomes among all disease states and different combinations of multimorbidity, except in patients with heart failure with preserved ejection fraction and heart failure without type 2 diabetes mellitus. SGLT2 inhibitors were found to decrease the risk of kidney failure in patients with type 2 diabetes mellitus and also in those with CKD. BACKGROUND: The effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on kidney outcomes in patients with varying combinations of heart failure, CKD, and type 2 diabetes mellitus have not been quantified. METHODS: PubMed and Scopus were queried up to December 2023 for primary and secondary analyses of placebo-controlled trials of SGLT2is in patients with heart failure, CKD, or type 2 diabetes mellitus. Outcomes of interest were composite kidney end point (combination of eGFR <15 ml/min per 1.73 m2, sustained doubling of serum creatinine, varying percent change in eGFR, and need for KRT), rate of eGFR slope decline, and albuminuria progression. Hazard ratios (HRs) and mean differences with their 95% confidence intervals (CIs) were extracted onto an Excel sheet, and the results were then pooled using a random-effect model through Review Manager (version 5.3, Cochrane Collaboration). RESULTS: Eleven trials (n=80,928 patients) were included. Compared with the placebo, SGLT2is reduced the risk of the composite kidney end point by 41% (HR, 0.59; 95% CI, 0.42 to 0.83) in heart failure with reduced ejection fraction, 36% (HR, 0.64; 95% CI, 0.55 to 0.73) in CKD, and 38% (HR, 0.62; 95% CI, 0.56 to 0.69) in type 2 diabetes mellitus. A similar pattern of benefit was observed in combinations of these comorbidities and in patients without baseline heart failure, CKD, or type 2 diabetes mellitus. SGLT2is slowed the rate of eGFR slope decline and reduced the risk of sustained doubling of serum creatinine by 36% (HR, 0.64; 95% CI, 0.56 to 0.72) in the overall population, and a consistent effect on kidney outcomes was observed in most subpopulations with available data. CONCLUSIONS: SGLT2i improved kidney outcomes in cohorts with heart failure, CKD, and type 2 diabetes mellitus, and these effects were consistent across patients with different combinations of these comorbidities.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Siddiqi TJ, Cherney D, Siddiqui HF, et al. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions: A Systematic Review and Meta-Analyses. J Am Soc Nephrol. 2024. PMID: 39230974. doi:10.1681/ASN.0000000000000491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。